Jacobs Levy Equity Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
– Sell
-19,107
Closed -$113K – 1143
2020
Q3
$113K Sell
19,107
-140,517
-88% -$695K ﹤0.01% 994
2020
Q2
$822K Sell
159,624
-24,905
-13% -$157K 0.01% 708
2020
Q1
$668K Buy
184,529
+39,104
+27% +$194K 0.01% 708
2019
Q4
$908K Buy
+145,425
New +$1.07M 0.01% 705
2017
Q2
– Sell
-7,140
Closed -$42K – 1055
2017
Q1
$42K Sell
7,140
-21,813
-75% -$158K ﹤0.01% 899
2016
Q4
$156K Sell
28,953
-1,660
-5% -$11.1K ﹤0.01% 856
2016
Q3
$272K Buy
30,613
+1,690
+6% +$15.9K ﹤0.01% 833
2016
Q2
$278K Hold
28,923
– – 0.01% 904
2016
Q1
$266K Sell
28,923
-7,658
-21% -$75.8K 0.01% 906
2015
Q4
$461K Buy
36,581
+32,071
+711% +$381K 0.01% 568
2015
Q3
$55K Buy
4,510
+1,000
+28% +$14.5K ﹤0.01% 786
2015
Q2
$61K Sell
3,510
-9,572
-73% -$172K ﹤0.01% 779
2015
Q1
$190K Buy
13,082
+4,502
+52% +$49.2K ﹤0.01% 708
2014
Q4
$72K Sell
8,580
-12,949
-60% -$118K ﹤0.01% 793
2014
Q3
$239K Buy
+21,529
New +$274K ﹤0.01% 722

Other funds holding AVEO

Jacobs Levy Equity Management's AVEO Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2020, closing a stake of 19,107 shares — an estimated $113K sold.

Jacobs Levy Equity Management first reported a position in AVEO in Q3 2014 and held it in 15 quarters. The position peaked at $908K in Q4 2019. 65 funds tracked by Wall St. Rank hold AVEO as of Q4 2020.

  • Jacobs Levy Equity Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 19,107 AVEO Pharmaceuticals, Inc. shares in Q4 2020, an estimated $113K.
  • Jacobs Levy Equity Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2014 and held it in 15 quarters.
  • Jacobs Levy Equity Management's AVEO Pharmaceuticals, Inc. position peaked at $908K in Q4 2019.
  • 65 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.